StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell

SCYNEXIS (NASDAQ:SCYX) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Thursday.

SCYNEXIS Price Performance

Shares of SCYX stock opened at $0.93 on Thursday. The business’s fifty day moving average price is $1.08 and its 200 day moving average price is $1.25. SCYNEXIS has a 1-year low of $0.82 and a 1-year high of $3.07. The firm has a market capitalization of $35.37 million, a PE ratio of -1.26 and a beta of 1.67.

SCYNEXIS (NASDAQ:SCYX) last posted its earnings results on Wednesday, March 12th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.13. The company had revenue of $0.98 million for the quarter. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%.

Institutional Trading of SCYNEXIS

Several large investors have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new stake in SCYNEXIS in the fourth quarter valued at $53,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in SCYNEXIS by 22.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 195,393 shares of the company’s stock valued at $236,000 after purchasing an additional 35,233 shares during the last quarter. Millennium Management LLC acquired a new stake in SCYNEXIS in the fourth quarter valued at $31,000. Jane Street Group LLC acquired a new stake in SCYNEXIS in the fourth quarter valued at $32,000. Finally, Northern Trust Corp grew its holdings in SCYNEXIS by 51.9% in the fourth quarter. Northern Trust Corp now owns 153,518 shares of the company’s stock valued at $186,000 after purchasing an additional 52,466 shares during the last quarter. Institutional investors and hedge funds own 54.37% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.